New study aims to boost heart failure drug adherence

NCT ID NCT07560982

Recruiting now Knowledge-focused Sponsor: Università Vita-Salute San Raffaele Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 07, 2026 · Updated 3 times

Summary

This observational study will track 300 adults with advanced heart failure to see how well they follow a four-medication treatment plan. Researchers will also measure quality of life using standard questionnaires. The goal is to understand real-world adherence and identify areas for improvement.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: beta-blocker, mineralocorticoid receptor antagonist, SGLT2 inhibitor, renin-angiotensin-aldosterone system drug
What this could lead to: If successful, this study could show that a structured approach helps more patients get the right heart failure medications, potentially improving survival and quality of life.
What could go wrong: This is an observational study, not a treatment trial, so it cannot prove cause and effect. Results may not apply to all heart failure patients, and adherence may still be low despite the strategy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

advanced heart failure heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEART FAILURE

Contacts and locations

Locations

ASST Ospedale Papa Giovanni XXIII
NOT_YET_RECRUITING

Bergamo, 24127, Italy
IRCCS Ospedale San Raffaele
RECRUITING

Milan, 20132, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.